Search results
Showing 31 to 45 of 49 results for diabetic medicine
Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)
Evidence-based recommendations on aflibercept solution for injection (Eylea) for treating wet age-related macular degeneration in adults.
Woundchek Protease Status for assessing elevated protease status in chronic wounds (MIB83)
NICE has developed a medtech innovation briefing (MIB) on the Woundchek Protease Status for assessing elevated protease status in chronic wounds .
Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged
variation existing between GP practices. This project was undertaken by the Medicines Management (MM) Team to support primary care...
contact casting, hyperbaric oxygen therapy and surgical debridement for diabetic foot problems. CG119/1
project demonstrated implementation of the key principles of the NICE Medicines Optimisation (MO) guidance (NG5), specifically by...
Transient loss of consciousness ('blackouts') in over 16s (CG109)
This guideline covers assessment, diagnosis and referral for people over 16 who have had a transient loss of consciousness (TLoC; also called a blackout). It aims to improve care for people with TLoC by specifying the most effective assessments and recommending when to refer to a specialist.
Pharmacist (ICP) is an innovative community based role where pharmacists lead medicines optimisation within various health and social...
Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)
Summary of the evidence on oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia to inform local NHS planning and decision-making
Help to Care Mobile App: Supporting care workers and carers to identify and prevent deterioration
Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes
NICE has developed a medtech innovation briefing (MIB) on FreeStyle Libre for glucose monitoring .
Interim methods guide for developing good practice guidance (PMG15)
Interim methods guide for developing good practice guidance
Type 2 diabetes prevention: population and community-level interventions (PH35)
This guideline covers preventing type 2 diabetes in adult populations and communities who are at high risk. It aims to promote a healthy diet and physical activity at community and population level, and recommends how to tailor services for people in ethnic communities and other groups who are particularly at risk of type 2 diabetes.
Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)
Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for treating wet age-related macular oedema in adults.